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BCL-6 Represses Genes that Function
in Lymphocyte Differentiation, Inflammation,
and Cell Cycle Control
burst of low-affinity antibody (Fukuda et al., 1997).
Whereas GC differentiation is blocked in BCL-6-defi-
cient mice, plasmacytic differentiation within the PALS
occurs normally (Fukuda et al., 1997). These observa-
tions suggest that BCL-6 controls a cell fate decision
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made by antigen-specific B cells, with high BCL-6 pro-National Cancer Institute
tein expression promoting GC differentiation and block-Bethesda, Maryland 20892
ing plasmacytic differentiation within the PALS. BCL-6
may also regulate post-GC plasmacytic differentiation.
While most GC B cells express BCL-6 protein, a minority
do not and instead express MUM1/IRF-4, a gene highlySummary
expressed in plasma cells (Falini et al., 2000). These
BCL-6-negative GC B cells include cells with plas-BCL-6, a transcriptional repressor frequently translo-
macytic morphology and may represent cells that arecated in lymphomas, regulates germinal center B cell
terminally differentiating as they exit the GC (Falini etdifferentiation and inflammation. DNA microarray screen-
al., 2000). Thus, plasmacytic differentiation, both pre-ing identified genes repressed by BCL-6, including
and post-GC, occurs only in the absence of BCL-6 ex-many lymphocyte activation genes, suggesting that
pression.BCL-6 modulates B cell receptor signals. BCL-6 re-
Roughly one-sixth of all B cell non-Hodgkin's lympho-
pression of two chemokine genes, MIP-1a and IP-10, mas have translocations of the BCL-6 gene, making
may also attenuate inflammatory responses. Blimp-1, BCL-6 one of the most frequently translocated genes
another BCL-6 target, is important for plasmacytic dif- in these cancers (reviewed in Dalla-Favera et al., 1999;
ferentiation. Since BCL-6 expression is silenced in Staudt et al., 1999). An attractive hypothesis is that
plasma cells, repression of blimp-1 by BCL-6 may con- BCL-6 translocations cause non-Hodgkin's lymphomas
trol plasmacytic differentiation. Indeed, inhibition of by coopting BCL-6's regulatory functions during B cell
BCL-6 function initiated changes indicative of plas- differentiation. In keeping with this idea, the BCL-6
macytic differentiation, including decreased expres- translocations do not disrupt the BCL-6 coding region
sion of c-Myc and increased expression of the cell but invariably substitute the BCL-6 promoter with a vari-
cycle inhibitor p27kip1. These data suggest that malig- ety of other promoters. Thus, BCL-6 translocations likely
cause transformation of B cells by deregulating the ex-nant transformation by BCL-6 involves inhibition of
pression of normal BCL-6 protein.differentiation and enhanced proliferation.
The aim of the present study was to discover the
molecular pathways regulated by BCL-6 in order to un-
Introduction derstand how BCL-6 controls immune responses and
promotes the formation of lymphomas. Although the
The transcriptional repressor BCL-6 has emerged as a consensus DNA binding site of BCL-6 has been defined
multifunctional regulator of lymphocyte differentiation (Baron et al., 1995; Seyfert et al., 1996), the genomic
and immune responses (reviewed in Dalla-Favera et al., targets of BCL-6 repression remain largely unknown.
1999; Staudt et al., 1999). BCL-6 mutant mice display The BCL-6 consensus binding site resembles the ªGASº
two prominent phenotypes: a failure to form germinal motif recognized by the STAT family of transcription
centers during a T cell±dependent immune response factors, raising speculation that BCL-6 may repress
and a fatal inflammatory disease distinguished by the some cytokine response genes (Dent et al., 1997; Gupta
presence of T helper type 2 (TH2) cells (Dent et al., et al., 1999; Harris et al., 1999). To comprehensively
1997; Fukuda et al., 1997; Ye et al., 1997). Although the identify BCL-6 target genes, we used Lymphochip mi-
molecular mechanisms underlying these phenotypes croarrays (Alizadeh et al., 1999, 2000). BCL-6 was found
are largely unknown, clues to the function of BCL-6 to repress a number of genes involved in B cell activation
come from its expression pattern. Although BCL-6 and terminal differentiation, inflammation, and cell cycle
mRNA can be detected in many tissues (Allman et al., regulation, providing rich insights into the roles BCL-6
1996), its protein expression is limited mainly to lympho- plays in the immune system and in human lymphomas.
cytes (Cattoretti et al., 1995; Onizuka et al., 1995; Allman
et al., 1996), with the highest level of BCL-6 protein Results
expressed in germinal center (GC) B cells. BCL-6 protein
expression in B cells is exquisitely regulated following BCL-6 Expression Systems
antigen encounter. Nascent pre-GC B cells upregulate To screen for BCL-6 target genes, we designed indepen-
BCL-6 protein, migrate to the follicular area, and initiate dent and complementary cellular systems in which BCL-6
GC formation (Fukuda et al., 1997). In contrast, antigen- function could be positively or negatively modulated.
specific B cells that do not upregulate BCL-6 protein Gain-of-function systems were created by introducing
expression differentiate in the periarteriolar lymphoid full-length (FL) BCL-6 into cell lines lacking endogenous
sheath (PALS) into plasmablasts and provide an initial BCL-6 protein expression (Figure 1A). Loss-of-function
systems were created by expressing a dominant-nega-
tive form of BCL-6, consisting solely of the BCL-6 zinc* To whom correspondence should be addressed (e-mail: lstaudt@
box-l.nih.gov). finger (ZnF) DNA binding domain, in cells that normally
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Figure 1. BCL-6 Expression Systems
(A±D) Cell systems in which BCL-6 activity was manipulated. See text for details.
(E±F) Detection of FLERD and ZnFERD proteins by immunofluoresence. WI-L2 cells carrying the FLERD vector (E) and Raji cells transduced
with the ZnFERD virus (F) were treated with ethanol (noninducer) or estradiol (inducer) and then immunostained to detect the subcellular
localization of these BCL-6-estrogen receptor fusion proteins.
express BCL-6 protein (Figure 1B). The BCL-6 ZnF do- synthesis inhibitors, which permits the identification of
gene expression changes that are primary effects of themain does not repress transcription in transient trans-
fection assays (Seyfert et al., 1996) and should thus transcription factor. Repression by inducible BCL-6 is
apparently due to its translocation from cytoplasm toblock the ability of endogenous BCL-6 to repress tran-
scription of its target genes. In most experiments, cell nucleus upon binding estradiol, as demonstrated in a
stable transfectant of the WI-L2 cell line (Figure 1E). Thelines were transduced with bicistronic retroviruses ex-
pressing various forms of BCL-6 together with a puromy- inducible, dominant-negative form of BCL-6 (ZnFERD)
was found in both the cytoplasm and nucleus, but uponcin resistance gene, allowing rapid selection of poly-
clonal populations for analysis. estradiol addition, ZnFERD moved quantitatively to the
nucleus (Figure 1F). The ability of ZnFERD to blockTo more directly identify BCL-6 targets, we created
two inducible forms of BCL-6 by fusing either full-length BCL-6 function may be due in part to its redistribution
and in part to a conformational effect on its ability toBCL-6 or its ZnF domain to the ligand binding domain
of the estrogen receptor (ERD; Figures 1C and 1D), interact with target genes and to act as an activator (via
the ERD) of transcription.allowing regulation of these proteins by estradiol. Typi-
cally, estradiol addition causes the translocation of tran-
scription factor fusion proteins from the cytoplasm to
the nucleus (Briegel et al., 1996). In some cases, the Identification of BCL-6 Target Genes
Using the systems described above, we studied thesubcellular localization is less affected, and regulation
presumably involves an alteration in the function of the effect of manipulating BCL-6 function on the expression
of genes represented on Lymphochip microarrays (Ali-transcription factor by the conformational changes in
the ERD (Francis et al., 1995), which can itself act as a zadeh et al., 1999, 2000). Each experiment compared
relative gene expression in two cell samples, typicallytranscriptional activation domain (Cavailles et al., 1994).
Since the inducible functions of ER fusion proteins do cells retrovirally transduced with a form of BCL-6 and
cells transduced with a control retrovirus. Total RNA wasnot require new protein synthesis, induction of these
proteins can be conducted in the presence of protein used as a template to make cDNA probes, incorporating
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either fluorescently labeled Cy3-dUTP (green) or Cy5-
dUTP (red). Probes were mixed and hybridized to a sin-
gle microarray. The hybridization of the two probes to
each microarray spot was quantitated, and the fluores-
cence intensity ratio (Cy5/Cy3) was calculated as a rela-
tive measure of gene expression. For data analysis, a
color scale was used to represent the ratios as colored
boxes arranged in a matrix (Figure 2A; Alizadeh et al.,
2000). Probe labeling for these experiments was de-
signed such that genes that were repressed by introduc-
tion of BCL-6 into a BCL-6 null cell line, and genes that
were induced by interference with BCL-6 in a BCL-6-
positive cell line appear red in Figure 2A (i.e., Cy5/
Cy3 . 1).
In this initial screen, 13 arrays (representative of over
30 experiments) yielded ~80,000 individual measures of
gene expression. The most likely BCL-6 target genes
are those whose mRNA levels were changed in more
than one cell type by manipulation of BCL-6 function.
Figure 2A presents the 14 genes that met this criterion;
expression levels of other genes were unchanged or
altered in a cell line±specific manner and not included
in this analysis (data not shown). These putative BCL-6
target genes were both repressed by the expression of
full-length BCL-6 in BCL-6 null cells (K562, WI-L2, or
SUDHL5) and induced (derepressed) by the expression
of dominant-negative BCL-6 in cells expressing endoge-
nous BCL-6 (Raji or BJAB). One previously proposed
BCL-6 target gene, CD23 (Dent et al., 1997; Gupta et
al., 1999), was not identified in any of the present cell
systems, whereas another potential BCL-6 target gene,
sterile e (Harris et al., 1999), was not included on the
arrays used in this study.
To better identify which genes may be direct targets
of BCL-6 repression, some experiments with inducible
estrogen receptor fusion proteins were performed in the
presence of the protein synthesis inhibitor cyclohexi- Figure 2. Microarray Screening for BCL-6 Target Genes
mide. Most of the genes in Figure 2A, with the possible (A) Cell line microarray analysis. Each column is a single experiment
exception of CD44, p27kip1, and Id2, were altered in comparing two cDNA populations, one labeled red (Cy5) and one
labeled green (Cy3). Each row represents data from a single cDNAtheir expression despite inhibition of new protein syn-
microarray spot. The red-to-green (Cy5/Cy3) ratio reflects hybridiza-thesis, indicating that BCL-6 may directly bind to the
tion to that spot, a measure of relative gene expression; intensityregulatory regions of these genes and repress their tran-
reflects the magnitude of the difference between the samples ac-scription.
cording the ratio color scale. Potential target genes repressed bySome cell type±specific differences in response to
BCL-6 (FL or FLERD, arrays 1±9) or derepressed by zinc fingerBCL-6 manipulation are seen in Figure 2A. For instance,
(ZnFERD, arrays 10±13) have Cy5/Cy3 ratios .1 and are red. Green
CXCR4 does not appear as a target gene in K562 or WI- indicates Cy5/Cy3 ratios ,1, black indicates no significant change
L2, while it is strongly repressed by BCL-6 in SUDHL5, in gene expression, and gray indicates the spot did not meet data
a finding explained by the lack of CXCR4 expression in selection criteria. The manner of stimulation for each cell line is
the former two cell lines and robust CXCR4 expression indicated (STIM) as well as the preaddition of the translation-inhibi-
tor cycloheximide (CHX).in the latter cell line (data not shown). In other cases,
(B) Expression of BCL-6 target genes in primary B cells. Microarraydifferences in regulatory factors in various cell types
data were obtained from http://llmpp.nih.gov/lymphoma and de-may be responsible for the variable effects of BCL-6
rived from previous Lymphochip gene expression analyses of rest-manipulation. For example, if a cell line lacks a positively
ing or mitogenically activated peripheral blood B cells (PBB) andacting transcription factor that is required for the expres-
germinal center B cells (GCB) (Alizadeh et al., 2000). Lane 1, PBB;sion of a given gene, derepression of BCL-6 in that cell
lane 2, PBB a-IgM, 6 hr; lane 3, PBB a-IgM 1 CD40 ligand (CD40L),
line will have no effect. Finally, the expression of some 6 hr; lane 4, PBB a-IgM 1 IL-4, 6 hr; lane 5, PBB a-IgM 1 CD40L 1
genes may be at or below the detection threshold of IL-4, 6 hr; lane 6, PBB a-IgM, 24 hr; lane 7, PBB a-IgM 1 CD40L,
microarrays and were therefore excluded from Figure 24 hr; lane 8, PBB a-IgM 1 IL-4, 24 hr; lane 9, PBB a-IgM 1 CD40L 1
2A. For example, the hybridization signal for blimp-1 in IL-4, 24 hr; lane 10, PBB a-IgM 1 CD40L, 48 hr; lane 11, PBB a-IgM 1
CD40L, 48 hr; lane12, GCB; and lane 13, GCB.SUDHL5 cells did not satisfy the data selection criteria
(Figure 2A), but Northern blot analysis demonstrated
that BCL-6 represses blimp-1 in this cell type (see
analysis (see http://lymphochip.nih.gov/shafferetal/). Ofbelow).
particular note was the fact that blimp-1 was repressedNorthern blot and semiquantitative RT-PCR analyses
by BCL-6 in SUDHL5 cells (Figure 3B) and induced byconfirmed the ability of BCL-6 to alter transcription of the
two dominant-negative BCL-6 proteins (ZnFERD [Figure14 target genes (Figure 3). There was close quantitative
agreement between the microarray and Northern blot 3B] and ZnF [Figure 3C]) in Raji cells. Interestingly,
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Figure 3. Northern Blot and RT-PCR Confirmation of BCL-6 Target Genes
(A) Northern blot analysis confirms BCL-6 repression of target genes. Cell line RNA was probed with fragments of the coding region for each
gene. A GAPDH probe was used as a control. The presence of active BCL-6 is indicated: SUDHL5 and K562, transduced with FL BCL-6 virus
(plus) or control virus (minus); WI-L2, transfected with FLERD, treated with estradiol (plus) or with EtOH (minus). Treatment with PMA and
ionomycin is indicated (plus).
(B) Northern blots for blimp-1 expression were performed as in (A) on RNA from SUDHL5 and Raji (6 estradiol pretreatment, followed by
interferon-g addition as indicated).
(C) RT-PCR analysis of target genes in K562 cells transduced with control or FL BCL-6 virus shows BCL-6 repression of target genes.
(D) RT-PCR analysis shows induction of target genes in Raji cells transduced with ZnF virus as compared to control cells after treatment with
PMA and ionomycin.
(E) RT-PCR analysis of Raji cells transduced with ZnFERD virus and stimulated by anti-IgM cross-linking shows induction of target genes in
the presence of the inducer (estradiol) but not the noninducer (EtOH). GAPDH and cyclin D3 amplification shows the equivalence of the mRNA
amplification and loading.
blimp-1 could be further induced by interferon-g treat- target genes are activation genes, induced 6±24 hr fol-
lowing stimulation. As predicted, most BCL-6 targetment of Raji cells only when ZnFERD was activated by
estradiol (Figure 3B). These results suggest that endoge- genes were expressed at much lower levels in GC B
cells (Figure 2B, lanes 12 and 13). Blimp-1, known tonous BCL-6 in Raji cells represses basal blimp-1 expres-
sion and makes the blimp-1 gene insensitive to tran- be preferentially expressed in plasma cells, was not
expressed detectably above background in any of thescriptional activation by other transcription factors,
including the STAT factors. B cell samples in Figure 2B (data not shown). These
results suggest that elevated BCL-6 protein in GC B
cells represses these target genes and that low levelsExpression of BCL-6 Target Genes During B Cell
of BCL-6 in mitogenically activated peripheral blood BActivation and Differentiation
cells (Allman et al., 1996) allow these activation genesSeveral of the BCL-6 target genes discovered in this
to be expressed.analysis are induced during activation of mature B cells
including CD69, CD44, cyclin D2, and MIP-1a (Camp et
al., 1991; Lopez-Cabrera et al., 1995; Solvason et al., Repression of Target Gene Promoters by BCL-6
The regulatory regions of several target genes were1996; Krzysiek et al., 1999). We predicted that most
BCL-6 target genes would be expressed at higher levels scanned for the consensus BCL-6 binding motif, 59-YTC
CTAGAR-39 (Seyfert et al., 1996). The human cyclin D2,in activated peripheral blood B cells than in GC B cells,
since BCL-6 protein is not expressed in resting or acti- MIP-1a, and CD69 genes were each found to have at
least one potential BCL-6 binding site. Remarkably, thevated B cells but is strongly expressed in most GC B
cells (Cattoretti et al., 1995; Onizuka et al., 1995; Allman BCL-6 site in the human cyclin D2 promoter is conserved
in both the mouse and rat cyclin D2 genes (Jun et al.,et al., 1996). A database of gene expression from normal
human B cells (Alizadeh et al., 2000; http://llmpp.nih. 1997; Yang et al., 1997), and the BCL-6 site in the human
MIP-1a promoter is conserved in the mouse MIP-1agov/lymphoma) was queried for the expression of each
of the BCL-6 target genes in resting peripheral blood B gene (Widmer et al., 1993). An electrophoretic mobility
shift DNA binding assay showed that BCL-6 protein wascells; in peripheral blood B cells activated in vitro with
various combinations of anti-IgM, CD40 ligand, and IL-4; able to bind specifically to the cyclin D2, MIP-1a, and
CD69 sites (see http://lymphochip.nih.gov/shafferetal/).and in GC B cells (Figure 2B). Many of the BCL-6
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Figure 4. Regulation of Target Gene Promoters by BCL-6
Transient transfection of luciferase reporters into BCL-6-negative target cell lines, with and without BCL-6 cotransfection, was performed.
Fold-repression of transcription by BCL-6, as measured by luciferase activity, was calculated by dividing luciferase activity in the absence
of BCL-6 by the activity in the presence of BCL-6 (normalized for transfection efficiency using a b-gal reporter). Control constructs consisted
of the SV40 promoter with nine tandem BCL-6 sites cloned upstream (pGL3 SV40 9x BCL-6, positive repression control) and the SV40 promoter
alone (pGL3 SV40, no BCL-6 sites) as a control for site-dependence of repression.
(A) Schematic of the human cyclin D2 promoters (wild type and mutant) with mutations disrupting the BCL-6 site indicated (X).
(B) Transient transfection shows BCL-6 repression of the human wild-type cyclin D2 promoter in SUDHL5 and K562 compared to the mutant
promoter.
(C) Schematic of the human MIP-1a promoter deletion constructs, with the BCL-6 site indicated.
(D and E) Transient transfection shows that BCL-6 repression of the human MIP-1a promoter in WI-L2 (D) and SUDHL5 (E) depends upon the
presence of the BCL-6 site.
To directly assess the ability of BCL-6 to repress tran- flow cytometry to monitor their expression in response
to alterations in BCL-6 activity (Figure 5). Both SUDHL5scription through these sites, we generated constructs
in which the human MIP-1a and cyclin D2 promoters and K562 express high constitutive levels of CD44 pro-
tein, and the expression of BCL-6 decreased cell surfacedrive expression of a luciferase reporter gene (Figures
4A and 4C). The activity of these reporters was mea- expression of CD44 substantially (Figure 5A). Similarly,
BCL-6 also decreased CD69 protein expression insured in the presence or absence of cotransfected
BCL-6 expression vectors. A series of MIP-1a promoter SUDHL5 cells (Figure 5D). In Raji cells, blocking BCL-6
function resulted in elevated surface expression ofconstructs showed that BCL-6 repressed promoter ac-
tivity of those constructs with a BCL-6 binding site (z13- Leu13 (Figure 5B), CD69 (Figure 5C), and CXCR4 (Figure
5E), suggesting that these genes are repressed by thefold) in both WI-L2 and SUDHL5 cells but had much less
effect on the activity of the construct lacking the BCL-6 endogenous BCL-6 protein in Raji cells.
We next asked whether manipulating BCL-6 functionbinding site (Figures 4D and 4E). Likewise, BCL-6 re-
pressed the activity of the wild-type cyclin D2 promoter could alter induced expression of target genes. Expres-
sion of BCL-6 in SUDHL5 substantially inhibited the abil-4- to 6.8-fold in SUDHL5 and K562 cells, and this repres-
sion was substantially reduced when the BCL-6 binding ity of PMA plus ionomycin to increase CD69 expression
(Figure 5D). In Raji cells, PMA plus ionomycin alonesite was mutated (Figure 4B). These data establish both
MIP-1a and cyclin D2 as direct targets of BCL-6 repres- did not induce CXCR4 (Figure 5E), while in cells with
sion acting through specific binding sites in their pro- dominant-negative BCL-6, blocking BCL-6 increased
moters. the basal expression of CXCR4 and promoted an addi-
tional increase in expression upon stimulation (Figure
5E). These observations suggest that the endogenousBCL-6 Alters Basal and Induced Levels of Target
BCL-6 protein in Raji cells blocks both constitutive andGene Proteins
induced expression of CXCR4.Since the candidate BCL-6 target genes CD44, Leu13,
CD69, and CXCR4 encode membrane proteins, we used Since PMA plus ionomycin is a pharmacological
Immunity
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Figure 5. Regulation of Surface Marker and Chemokine Expression by BCL-6
(A) Repression of CD44 by BCL-6 in SUDHL5 and K562. The green trace shows control cells; the blue trace represents BCL-6-virus transduced
cells. The black line shows staining with an isotype-matched, nonspecific control. Data are representative of two or more independent
infections.
(B) Derepression of 9±27/LEU13 by ZnFERD in Raji.
(C) Derepression of CD69 by ZnFERD in Raji.
(D) Repression of basal and inducible (6 PMA and ionomycin) CD69 by BCL-6 in SUDHL5.
(E) Derepression of CXCR4 by ZnFERD in Raji.
(F) Derepression and superinduction of CD69 by ZnFERD upon BCR cross-linking in BJAB. Cells were stained for CD69 in the absence (top
panel) or presence (lower panels) of anti-IgM. Cells were treated with ethanol or estradiol prior to addition of anti-IgM.
(G) Inducible MIP-1a expression is blocked by BCL-6. MIP-1a levels were measured in WI-L2 control cells (c) and WI-L2 FLERD cells (FL)
after treatment with EtOH (ET) or estradiol (ES).
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mimic of signaling through the B cell antigen receptor control mice showed a range of CD44 expression over
2 orders of magnitude (Figure 6B). In contrast, B cells(BCR), we tested whether the activation of gene expres-
sion by anti-IgM cross-linking of the BCR could also from the BCL-6 mutant mice had uniformly high CD44
expression, a phenotype associated with B cell activa-be augmented by blocking BCL-6 function. The EBV-
negative Burkitt's lymphoma cell line BJAB has been tion (Camp et al., 1991). Lastly, very few (z2%) of the B
cells from unimmunized heterozygous mice expressedstudied as a model for signaling through the B cell anti-
gen receptor (Miller et al., 1993). In unstimulated BJAB the lymphocyte activation marker CD69, and immuniza-
tion modestly increased the proportion of CD691 B cellscells transduced with dominant-negative BCL-6, estra-
diol treatment had no effect on surface CD69 expression to 8% (Figure 6C). In sharp contrast, 55% of the B cells
in BCL-6 mutant mice expressed CD69. This ªactivatedº(Figure 5F), in contrast to Raji cells (Figure 5C). When
BJAB cells were stimulated by BCR cross-linking, CD69 B cell phenotype (IgMlowCD44highCD691) was observed
in multiple BCL-6 mutant mice from independent littersexpression was increased, and this effect was greatly
enhanced by blocking BCL-6 (Figure 5F). In BJAB cells and had no apparent correlation with the health or age
of the BCL-6 mutant mice.transduced with control virus, estradiol treatment did
not superinduce CD69 expression following anti-IgM Given that BCL-6 mutant mice have an influx of inflam-
matory cells in the spleen when immunized (Dent et al.,stimulation. These findings suggest that BCL-6 inter-
feres with the activation of genes in response to signals 1997), we tested whether secretion of the chemokine
and inflammatory mediator MIP-1a is elevated in thesethrough the BCR.
The chemokines MIP-1a and IP-10 form an important mice. MIP-1a is induced and secreted by normal B cells
following mitogenic activation (Krzysiek et al., 1999). Weclass of BCL-6 target genes given that one of the promi-
nent phenotypes of BCL-6 mutant mice is a fatal inflam- therefore compared MIP-1a secretion by control and
BCL-6 mutant splenic B cells following in vitro activationmatory disease (Dent et al., 1997; Fukuda et al., 1997;
Ye et al., 1997). To confirm the results of the microarray with lipopolysaccaride (LPS). BCL-6 mutant B cells se-
creted 6.4-fold more MIP-1a after 3 days of culture withanalysis, we measured the secretion of these chemo-
kines by ELISA under conditions in which BCL-6 activity LPS than did heterozygous B cells (Figure 6D). This
result raises the possibility that the splenic inflammationwas altered. BCL-6 expression in WI-L2 cells inhibited
the constitutive secretion of MIP-1a (Figure 5G). Induc- that accompanies immunization of BCL-6 mutant mice
may be due, in part, to the elevated secretion of MIP-tion of dominant-negative BCL-6 in Raji cells increased
secretion of IP-10, suggesting that endogenous BCL-6 1a by B cells in the absence of BCL-6. The analysis of
BCL-6 mutant mice provides complementary geneticprotein represses the basal expression of the IP-10 gene
(Figure 5H). In the same cell system, blocking BCL-6 evidence that CD69, CD44, and MIP-1a are indeed tar-
gets of BCL-6 repression.alone did not increase the basal secretion of MIP-1a
(Figure 5I). Interestingly, blocking BCL-6 did enhance
the induction of MIP-1a following PMA plus ionomycin Dominant-Negative BCL-6 Alters Differentiation
treatment (Figure 5I). These results suggest that the Markers and Arrests Growth
endogenous BCL-6 protein in Raji cells represses acti- Earlier studies of Raji cells transduced with dominant-
vated transcription of the MIP-1a gene. Further, these negative BCL-6 were performed in the presence of the
data support a role for BCL-6 in the inhibition of chemo- protein synthesis inhibitor cycloheximide in order to
kine secretion by B cells. identify direct BCL-6 target genes (Figure 2A). To investi-
gate the downstream effects of blocking BCL-6 function
in the Raji cells, we repeated these experiments in theBCL-6 Target Genes in BCL-6 Mutant Mice
Given the ability of BCL-6 to repress genes involved in absence of cycloheximide, and monitored gene expres-
sion using Lymphochip microarrays at 3, 8, 24, and 48 hrB cell activation and differentiation in a variety of in vitro
systems, we next analyzed B cells from BCL-6 mutant after estradiol induction of ZnFERD. Inhibition of BCL-6
function in Raji cells altered the expression of cell cycle±mice (Dent et al., 1997). The expression of several BCL-6
target genes in splenic B cells from BCL-6 heterozygous regulated genes, B cell differentiation genes, interferon-
responsive genes, and the previously identified BCL-6control (1/2) and BCL-6 mutant (2/2) littermates was
analyzed by flow cytometry (Figure 6A). BCL-6 mutant target genes (Figure 7A; data not shown). A notable
member of the cell cycle±regulated class was c-myc, amice were found to have B cells with an activated cell
surface phenotype. First, when stained for expression gene that is repressed by blimp-1 (Lin et al., 1997). The
fact that blimp-1 is induced in Raji cells when BCL-6 isof the pan-B cell marker B220 and for surface IgM ex-
pression, B cells in BCL-6 mutant mice expressed 10- blocked (Figures 3B and 7A) suggests that the de-
creased c-myc expression is secondary to increasedfold lower levels of surface IgM than control littermates
(Figure 6A). This decrease in IgM staining is similar to blimp-1 expression. c-Myc protein was correspondingly
decreased under the same conditions (Figure 7B). Inter-that seen 2 days after immunization of control mice with
sheep red blood cells (Figure 6A). B cell activation is estingly, two genes that are activated by c-Myc, lactate
dehydrogenase (Shim et al., 1997) and ornithine decar-accompanied by a decrease in surface IgM expression
(Wheeler and Gordon, 1996), implying that BCL-6 mutant boxylase (Wagner et al., 1993), were also lowered in
expression with slightly delayed kinetics compared withB cells may be spontaneously activated in the absence
of deliberate immunization. Second, splenic B cells from c-myc (Figure 7A). A number of other cell cycle±related
(H) ZnFERD derepresses IP-10 production in Raji. Control (c) and ZnFERD (z) transduced pools were left untreated or treated with ethanol
(ET) or estradiol (ES).
(I) ZnFERD derepresses inducible MIP-1a production in Raji. Raji control (c) and ZnFERD (z) transduced pools were treated with ethanol (ET)
or estradiol (ES) alone or followed by PMA and ionomycin (plus). Secreted chemokine levels were determined in duplicate.
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Figure 6. Inappropriate B Cell Activation and Chemokine Secretion in BCL-6 Mutant Mice
(A±C) Flow cytometry of B cells from BCL-6 mutant (2/2) and control (1/2) littermates. BCL-6 (1/2) mice were also injected intraperitineally
(i.p.) with sheep red blood cells (srbc) two days prior to sacrifice (middle row). (A) Staining for the pan-B cell marker B220 (PE) and for surface
IgM (FITC). Percentages of B2201, IgMhi, and IgMlo cells are indicated in each panel. (B) Staining for IgM (FITC) and CD44 (PE). Percentages
of IgM1, CD44hi, and CD44lo cells are indicated in each panel. (C) Staining for B cells (B220, PE) and CD69 (FITC). Percentages of B2201,
CD69-positive and -negative B cells are indicated in each panel.
(D) B cells overexpress MIP-1a in the absence of BCL-6. Equal numbers of purified (CD191) BCL-6 heterozygous (1/2) and BCL-6 mutant
(2/2) B cells were cultured for 3 days with LPS. Supernatants were analyzed in duplicate by ELISA for secreted MIP-1a. Data from one of
two independent B cell purification/stimulation experiments are shown.
genes were also downregulated by blocking BCL-6, BCL-7A; Alizadeh et al., 2000) as were a number of
pan-B cell genes (CD19, CD37, CD79A, CD79B, Spi-B,while several growth arrest genes, including p27kip1,
were induced under these conditions (Figure 7A). and CD20) (Figures 7A and 7C). The expression of many
of these genes is also downregulated in plasma cellsProfound changes in cell cycle genes induced by
blocking BCL-6 function correlated with changes in cell (Liu and Banchereau, 1996). Conversely, genes that are
upregulated during terminal plasmacytic differentiationviability and cell cycle distribution. Cultures of ZnFERD-
transduced Raji cells treated with estradiol had fewer were induced (CD38, blimp-1, and MCL-1; Turner et al.,
1994; Liu and Banchereau, 1996) (Figures 7A and 7C).viable cells and more dead cells than similarly treated
control Raji cells (Figure 7D). Further, induction of However, this apparent plasmacytic differentiation was
incomplete as these cells failed to express the plasmaZnFERD arrested the cell cycle, as evidenced by accu-
mulation of cells in G1 phase and loss of cells in S and cell marker syndecan-1 and also upregulated MHC class
II, genes that are not typically expressed by plasmaG2/M phases (Figure 7E).
A number of B cell differentiation genes were altered cells.
in expression by interfering with BCL-6 function in Raji
cells, and many of these gene expression changes mim-
Discussionicked those that accompany normal plasma cell differ-
entiation. Several genes that are characteristically ex-
pressed in GC cells were downregulated when BCL-6 Using cDNA microarrays in a gene expression screen,
we identified genes that are potential targets of BCL-6function was blocked (CD10, A-myb, CD27, CD70, and
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Figure 7. Inhibition of BCL-6 Alters Differentiation Markers and Arrests Cell Division
(A) Gene expression changes following estradiol induction of control versus ZnFERD-transduced Raji cells. RNA was harvested before induction
(time 0) and at 3, 8, 24, and 48 hr after estradiol addition. RT-PCR for blimp-1 shows its induction in ZnFERD virus-transduced cells, while
control cells do not express blimp-1 (data not shown). Also shown are microarray data comparing control cells to ZnFERD-transduced cells.
Genes upregulated following blockade of BCL-6 function by ZnFERD are depicted in red; downregulated genes are depicted in green.
(B) Western blot analysis shows c-Myc downregulation in ZnFERD-induced cells compared to controls. The SP1 blot controls for quality and
loading lysates.
(C) Differentiation markers are altered by BCL-6 inhibition. Flow cytometric analysis for CD38 and CD19 were performed at 48 hr after estradiol
addition.
(D) Cell death increases when BCL-6 is inhibited.
(E) Cell cycle arrest follows BCL-6 inhibition. Control and ZnFERD-transduced cells were monitored for DNA content, as a measure of their
position in the cell cycle, over the course of estradiol induction.
(F) Hypothesis: the role of BCL-6 in B cell differentiation. Germinal center B cells express BCL-6, which represses genes such as p27kip1
and blimp-1, allowing other genes such as c-myc to promote rapid cell division while forestalling terminal differentiation. Terminal differentiation
to plasma cells occurs when BCL-6 expression terminates and target genes like blimp-1 initiate a new genetic program.
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repression. These target genes are functionally linked BCL-6 had quantitatively greater effect on the induced
expression of genes than on their basal expression. Forby their roles in B cell activation (CD69, CD44, EBI2,
example, repression of CD69 in SUDHL5 cells by BCL-6Id2, STAT1), B cell differentiation (blimp-1), inflammation
was more pronounced after stimulation with PMA plus(MIP-1a, IP-10), and cell cycle control (p27kip1, cyclin
ionomycin, a pharmacological mimic of BCR signaling.D2). Multiple independent and complementary lines of
Similarly, expression of dominant-negative BCL-6 in Rajievidence support the conclusion that these genes are
cells caused a greater increase in CXCR4 expression inBCL-6 targets. First, microarray data, along with confir-
cells stimulated with PMA plus ionomycin. Perhaps thematory Northern blot and RT-PCR analysis, showed that
clearest demonstration of this principle was the effect ofthese genes were repressed by ectopic expression of
dominant-negative BCL-6 on CD69 expression in BJABBCL-6 in BCL-6-negative cell lines and were activated
cells. Dominant-negative BCL-6 had no effect on basalby the expression of dominant-negative forms of BCL-6
CD69 levels in BJAB cells but led to augmented induc-in BCL-6-positive cell lines. Second, the mRNA levels
tion of CD69 following stimulation through the BCR.of most target genes, with the possible exception of
Since BCL-6 blocks expression of genes induced whenCD44, p27kip1, and Id2, could be altered by BCL-6 or
B cells are stimulated by antigen, the outcome of signal-its dominant-negative form in the presence of the protein
ing through the BCR in a GC B cell could be altered bysynthesis inhibitor cycloheximide. This implies that
the expression of BCL-6.these genes are direct targets of BCL-6 repression.
Blimp-1 is a transcriptional repressor which plays aThird, the promoter regions of three target genes, MIP-
key role in differentiation of B cells to plasma cells1a, cyclin D2, and CD69, were found to contain high-
(Turner et al., 1994). Upregulation of blimp-1 mRNA isaffinity BCL-6 binding sites. The BCL-6 binding sites in
an early event in the differentiation of mouse splenic Bthe MIP-1a and cyclin D2 promoters have been highly
cells into antibody-secreting preplasma cells (Soro et al.,conserved in evolution, and the promoters of these
1999), and enforced expression of blimp-1 is sufficient togenes were repressed by the expression of BCL-6 in
direct cells toward plasma cell differentiation (Turner ettransient transfection assays. Fourth, the protein prod-
al., 1994; Messika et al., 1998). Blimp-1 represses theucts of the CD44, Leu13, CD69, CXCR4, MIP-1a, and
transcription of c-Myc (Lin et al., 1997; Knodel et al.,IP-10 genes were correspondingly modulated by alter-
1999) and in B cells that are poised to differentiate toation of BCL-6 function. Finally, genetic disruption of
plasma cells, this drop in c-myc expression is integralBCL-6 in mice caused increased expression of three
to the process of terminal differentiation (Lin et al., 1997;BCL-6 target genes in B lymphocytes: CD69, CD44, and
Messika et al., 1998). Therefore, the repression of blimp-1MIP-1a. The functions of these potential BCL-6 target
by BCL-6 could be a pivotal event controlling the differ-genes shed considerable light on the molecular mecha-
entiation of GC B cells to plasma cells.nisms by which BCL-6 regulates GC formation and in-
We observed that blockade of BCL-6 function in Rajiflammation and causes lymphoma when dysregulated.
cells not only induced blimp-1 expression but also de-Further work will be required to define the precise
creased c-myc expression and arrested the cell cyclemolecular mechanisms by which BCL-6 alters the mRNA
in G1. Since c-Myc regulates the transition from G1 tolevels of each of these candidate target genes. Some
S phase (Carman et al., 1996), the decrease in c-myctarget genes, such as MIP-1a, cyclin D2, and CD69, may
expression may be responsible, in part, for the observedbe regulated by direct binding of BCL-6 to cis-elements
cell cycle arrest. These results are consistent with ain their promoters. BCL-6 can also interact with other
model in which BCL-6 inhibits blimp-1, which in turntranscription factors (Davies et al., 1999; Gupta et al.,
inhibits c-myc (Figure 7F). Thus, elevated levels of BCL-61999), and thus it is possible that some of the target
in GC B cells would result in higher levels of c-Myc,genes defined here result from interference or synergism
whereas loss of BCL-6 in plasma cells would result inbetween BCL-6 and these other factors.
lower levels of c-Myc.
Expression of several other B cell differentiation genes
Regulation of B Cell Differentiation by BCL-6 was altered by inhibition of BCL-6 function, many of
Many of the identified target genes are regulated in their which are reminiscent of normal plasmacytic differentia-
expression during B cell activation and differentiation tion. A number of germinal center±restricted genes (Ali-
and thus are attractive candidates for BCL-6 regulation. zadeh et al., 2000) were downregulated (CD10, A-myb,
All of the BCL-6 target genes were found to be ex- and BCL-7A) as were CD19 and CD20, markers that are
pressed at low or undetectable levels in GC B cells known to decrease during plasmacytic differentiation.
and were expressed in resting and/or in vitro activated Conversely, CD38 was upregulated as also occurs in
human peripheral blood B cells. This observation is con- plasma cells (Liu and Banchereau, 1996). Furthermore,
sistent with the 3- to 30-fold higher expression of BCL-6 blockade of BCL-6 caused cell cycle arrest, reminiscent
protein in GC B cells compared with resting peripheral of the arrest accompanying terminal plasma cell differ-
blood B cells and with the downregulation of BCL-6 entiation. However, some plasma cell markers such as
expression during mitogenic activation of peripheral syndecan-1 were not induced in Raji cells under these
blood B cells (Allman et al., 1996). Thus, upregulation conditions, indicating that BCL-6 inhibition causes only
of BCL-6 protein expression in GC B cells contributes partial plasmacytic differentiation in this cell system.
to the characteristic gene expression signature of this Taken together, these findings suggest that BCL-6 is
stage of differentiation (Alizadeh et al., 2000). a key upstream gatekeeper of terminal B cell differentia-
An important theme uniting many of the BCL-6 target tion (Figure 7F). Consistent with this model is the ob-
genes is induction via signals through the BCR. Several servation that unimmunized BCL-6 mutant mice have
genes (CD69, CD44, cyclin D2, STAT1, MIP-1a, and IP- elevated numbers of IgG- and IgE-expressing plasmacy-
10) were shown to be B cell activation genes by microar- toid cells (Ye et al., 1997). BCL-6 may block plasmacytic
ray analysis (Alizadeh et al., 2000) and by more conven- differentiation at two distinct points during a normal
antigen response. In the initial days after immunization,tional assays. Indeed, in some experimental systems,
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a few BCL-6-expressing, pre-GC B cells appear in the cause either growth arrest and terminal plasmacytic dif-
ferentiation or apoptosis. Because BCL-6 repressesPALS, whereas B cells undergoing plasmacytic differen-
tiation in the PALS do not express BCL-6 (Fukuda et al., blimp-1, which in turn represses c-myc, BCL-6 translo-
cations might be considered functionally equivalent to1997). Thus, the elevated expression of BCL-6 in some
B cells early in the antigen response may skew these B c-myc translocations. In this regard, it is notable that
Burkitt's lymphomas, which invariably have c-myc trans-cells toward a germinal center fate and away from a
plasmacytic fate. This model further suggests that the locations, are one of the few non-Hodgkin's lymphoma
subtypes that almost never have BCL-6 translocationscontinued expression of BCL-6 in most GC B cells is
required to repress blimp-1 and block terminal plasma (reviewed in Dalla-Favera et al., 1999; Staudt et al., 1999).
Conversely, non-Hodgkin's lymphomas with BCL-6 trans-cell differentiation. Interestingly, while most B cells in
the germinal center express BCL-6 protein, a minority locations do not often carry c-myc translocations (Mitel-
man, 1994).of GC cells with either centrocytic or plasmacytic mor-
phology do not and instead express MUM1/IRF-4, a The repression of p27kip1 by BCL-6 might also be
critical for malignant transformation by BCL-6. p27kip1transcription factor that is highly expressed in plas-
macytic cells (Falini et al., 2000). Given the repression arrests the cell cycle in response to extrinsic signals at
the G1-to-S phase transition by binding to G1 cyclin-of blimp-1 by BCL-6, downregulation of BCL-6 may be
a required first step in the decision of a GC B cell to dependent kinases (Polyak et al., 1994; Toyoshima and
Hunter, 1994). Mice deficient in p27kip1 develop multior-initiate plasmacytic differentiation.
gan hyperplasia and tumors, emphasizing its critical role
as a tumor suppressor (Fero et al., 1996; Kiyokawa etRegulation of Inflammatory Responses by BCL-6
al., 1996; Nakayama et al., 1996). Even heterozygousA prominent and fatal phenotype of BCL-6 mutant mice
p27kip1 mutant mice develop tumors more readily thanis an inflammatory myocarditis and pulmonary vasculitis
wild-type mice, and many human tumors have hemizy-that develops shortly after birth. This inflammation is
gous loss of one allele of p27kip1 (Fero et al., 1998).characterized by a mixture of lymphoid and myeloid cell
Small changes in p27kip1 levels can therefore affecttypes and has the hallmarks of a Th2 process (Dent
malignant transformation. Germinal center centroblastset al., 1997; Fukuda et al., 1997; Ye et al., 1997). The
have one of the most rapid doubling times of any primaryobservation that BCL-6 represses the chemokines
human cell type (z6 hr) and express no detectableMIP-1a and IP-10 suggests additional pathogenic
p27kip1 (Quintanilla-Martinez et al., 1998; Sanchez-mechanisms that may contribute to the inflammatory
Beato et al., 1999). Therefore, BCL-6 repression ofresponses of BCL-6 mutant mice. MIP-1a, a CC chemo-
p27kip1 may permit rapid cell cycle transit in both nor-kine, recruits inflammatory cells, including lymphocytes,
mal GC B cells and in BCL-6-expressing lymphomas.monocytes, eosinophils, and mast cells, to sites of im-
Translocation of BCL-6 can, in some cases, be themune challenge (Schall et al., 1993; Lukacs et al., 1995).
sole chromosomal abnormality detectable in a diffuseIP-10, a CXC chemokine, was originally identified as a
large B cell lymphoma by standard cytogenetic analysischemoattractant specific for activated T cells but can
(see Mitelman, 1994), suggesting that these transloca-also recruit B cells, monocytes, and NK cells during
tions occur early in the transformation sequence. Thisimmune responses (reviewed in Farber, 1997). Both MIP-
pivotal role for BCL-6 in lymphomagenesis is now under-1a and IP-10 are induced by BCR stimulation, and thus
standable given that BCL-6 may block terminal differen-an important role for BCL-6 may be to blunt the expres-
tiation by repressing blimp-1 and maintain proliferationsion of these chemokines by B cells during an immune
by repressing p27kip1. Consequently, it is worth consid-response. Dysregulated secretion of MIP-1a and/or IP-
ering whether inhibition of BCL-6 function might be a10 may therefore contribute to the splenic inflammation
useful therapeutic strategy in some B cell non-Hodgkin'sthat occurs in BCL-6 mutant mice following immuniza-
lymphomas.tion (Dent et al., 1997; Fukuda et al., 1997; Ye et al.,
1997). Interestingly, MIP-1a has been shown to play a
role in experimental models of myocarditis and pulmo- Experimental Procedures
nary inflammation, and this inflammatory response does
More detailed methods can be found at: http://lymphochip.nih.gov/not occur in mice that are genetically deficient in MIP-
shafferetal/.1a expression (Cook et al., 1995). Further experiments
will be needed to test directly whether abnormal expres-
Cell Culture, Retroviral Constructs, and Retrovirus Infectionsion of MIP-1a, or other chemokines, contributes to
Cell lines were maintained in RPMI 1640 media (no phenol red,inflammatory disease in BCL-6-deficient mice.
GIBCO±BRL) with 10% fetal calf serum (charcoal/dextran absorbed,
HyClone) and pen/strep (GIBCO±BRL). The stable WI-L2 line (WI-
Implications for Lymphomagenesis L2 FLERD) expressing full-length BCL-6 fused to a portion of the
The translocations of BCL-6 in non-Hodgkin's lympho- estrogen receptor was maintained in 1mg/ml. The Phoenix retroviral
mas alter the BCL-6 locus by substituting strong, consti- system was used to express various proteins in target cells (http://
www.stanford.edu/group/nolan/phoenix_info.html). The bicistronictutively active promoters for the BCL-6 promoter (re-
pBMN-IRES-Lyt2 was modified by replacing mouse Lyt2 with a pu-viewed in Dalla-Favera et al., 1999; Staudt et al., 1999).
romycin resistance gene. Each retroviral construct (containing aThese translocations most likely prevent the downregu-
form of BCL-6 plus the puromycin resistance gene or the puromycinlation of BCL-6 transcription that occurs upon plas-
resistance gene alone to generate a control population) was trans-macytic differentiation. Lymphomas with BCL-6 translo-
fected into the amphitrophic Phoenix packaging line to make a viral
cations would therefore maintain repression of BCL-6 supernatant used for spin-infection (Quong et al., 1999). Transduced
target genes, trapping these cells at the germinal center cells were selected with empirically determined concentrations of
stage of differentiation. Repression of blimp-1 by BCL-6 puromycin (Sigma). Estrogen receptor fusions with BCL-6 (FLERD
might be especially critical for malignant transformation. and ZnFERD) were engineered (see http://lymphochip.nih.gov/
shafferetal/) and induced with b-estradiol (1 mM, Sigma).As a transcriptional repressor of c-myc, blimp-1 can
Immunity
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Cell Stimulation Cell Viability and Cell Cycle Analysis
Equal numbers of Raji control and ZnFERD-transduced cells wereCells were stimulated with phorbol myristate acetate (PMA, 10 ng/
ml, Sigma) and the calcium ionophore ionomycin (1 mg/ml, Sigma). added to fresh media. Viability was determined by trypan blue exclu-
sion. For cell cycle analysis, cells were harvested, resuspended inCells were also treated with goat anti-human IgM (Fab'2, Jackson
Immunoresearch) and interferon-g (10 ng/ml, R&D systems). Some PBS, and fixed with EtOH. Cells were then placed on ice for 20 min,
pelleted, and resuspended in 1 ml of 13 PBS/1% FBS. Cells werecells were also treated with cycloheximide (1 mg/ml, Sigma) to arrest
protein synthesis, then treated with estradiol to induce ERD-fusion pelleted again, resuspended in a solution of 13 PBS/2.5 mM EDTA/
10 mg/ml propidium iodide (Sigma) and 250 mg/ml RNase A for 40proteins.
min at 378C, then analyzed by flow cytometry to determine the
proportion of cells in each phase of the cell cycle.
RNA Preparation and cDNA Microarray Analysis
Total RNA was prepared by the Trizol method (GIBCO±BRL).
Western Blotting
Lymphochip cDNA microarrays were prepared and hybridized as
Western blots were performed as described (Seyfert et al., 1996).
described (Alizadeh et al., 2000). Microarrays were analyzed on a
Rabbit-a-c-Myc and Rabbit-a-SP1 antibodies (Santa Cruz) were
GenePix (AXON) scanner at 635 nm (CY-5, red) and 523 nm (CY-3,
used with a secondary HRP-conjugated antibody (Amersham).
green) wavelengths. Spot data were analyzed using software devel-
Membranes were developed with ECL reagents (Amersham).
oped at the National Insitutes of Health and the programs Cluster
and Treeview (M. Eisen; http://www.microarrays.org/software
Animal Generation and Handling[Eisen et al., 1998]). Purification, stimulation, and analysis of primary
Generation and handling of BCL-6 mutant mice has been describedhuman B cell populations are described in Alizadeh et al., 2000).
(Dent et al., 1997). Healthy mice were sacrificed between the agesDetails for the samples compared in Figure 2A are at http://
of 4 and 6 weeks for analysis. Mice were maintained according tolymphochip.nih.gov/shafferetal/.
the guidelines of the National Institutes of Health Office of Animal
Care and Use.
Northern Blots and Semiquantitative RT-PCR
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Promoter Analysis
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